HUE025513T2 - TNF-alfával kapcsolatos rendellenességek kezelése - Google Patents

TNF-alfával kapcsolatos rendellenességek kezelése

Info

Publication number
HUE025513T2
HUE025513T2 HUE10742811A HUE10742811A HUE025513T2 HU E025513 T2 HUE025513 T2 HU E025513T2 HU E10742811 A HUE10742811 A HU E10742811A HU E10742811 A HUE10742811 A HU E10742811A HU E025513 T2 HUE025513 T2 HU E025513T2
Authority
HU
Hungary
Prior art keywords
scd
pyridazin
inhibitors
ones
derivatives
Prior art date
Application number
HUE10742811A
Other languages
English (en)
Hungarian (hu)
Inventor
Elisabeth Dupont-Passelaigue
Samuel Mialhe
Jean-Pierre Rieu
Didier Junquero
Karine Valeille
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE025513T2 publication Critical patent/HUE025513T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HUE10742811A 2009-08-05 2010-08-05 TNF-alfával kapcsolatos rendellenességek kezelése HUE025513T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0955504A FR2948939B1 (fr) 2009-08-05 2009-08-05 Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine

Publications (1)

Publication Number Publication Date
HUE025513T2 true HUE025513T2 (hu) 2016-05-30

Family

ID=41582079

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10742811A HUE025513T2 (hu) 2009-08-05 2010-08-05 TNF-alfával kapcsolatos rendellenességek kezelése

Country Status (10)

Country Link
US (1) US8946225B2 (enExample)
EP (1) EP2462121B1 (enExample)
JP (1) JP5901520B2 (enExample)
AR (1) AR077715A1 (enExample)
ES (1) ES2536841T3 (enExample)
FR (1) FR2948939B1 (enExample)
HU (1) HUE025513T2 (enExample)
PL (1) PL2462121T3 (enExample)
TW (1) TW201109313A (enExample)
WO (1) WO2011015629A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
BR112014008590A2 (pt) * 2011-10-15 2017-10-24 Genentech Inc métodos de uso de antagonistas de scd1
WO2013085957A1 (en) * 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
US9238658B2 (en) 2011-12-06 2016-01-19 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
CA2997131C (en) 2015-09-18 2021-05-25 University Of Miyazaki Long-acting adrenomedullin derivative
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) * 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
AU2004261249B2 (en) * 2003-07-30 2008-09-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005074938A1 (ja) * 2004-02-09 2005-08-18 Nissan Chemical Industries, Ltd. 血管内膜肥厚抑制薬
JP2009519984A (ja) * 2005-12-20 2009-05-21 メルク フロスト カナダ リミテツド ステアロイル−補酵素δ−９デサチュラーゼ阻害剤としての芳香族複素環化合物
JP4984701B2 (ja) * 2006-07-18 2012-07-25 富士ゼロックス株式会社 Ｌｅｄプリントヘッドの製造方法
JP4695565B2 (ja) * 2006-08-21 2011-06-08 株式会社リコー 画像形成装置
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
ATE488499T1 (de) 2007-08-08 2010-12-15 Graceway Pharmaceuticals Llc Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus

Also Published As

Publication number Publication date
ES2536841T3 (es) 2015-05-29
EP2462121A1 (en) 2012-06-13
FR2948939A1 (fr) 2011-02-11
US8946225B2 (en) 2015-02-03
PL2462121T3 (pl) 2015-07-31
US20120178678A1 (en) 2012-07-12
JP5901520B2 (ja) 2016-04-13
AR077715A1 (es) 2011-09-14
FR2948939B1 (fr) 2013-03-22
EP2462121B1 (en) 2015-02-18
JP2013501031A (ja) 2013-01-10
TW201109313A (en) 2011-03-16
WO2011015629A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
PL2462121T3 (pl) Pochodne 2H-pirydazyn-3-onu, ich wytwarzanie i zastosowanie jako inhibitorów SCD-1
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
AP3179A (en) Benzofuranyl derivatives used as glucokinase inhibitors
IL215251A0 (en) Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG10201405568UA (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PL2719699T3 (pl) Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
IL206544A0 (en) Methods of preparing quinazolinone derivatives
ZA201201366B (en) Heterocycic derivatives as inhibitors of glutaminyl cyclase
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
IL215368A0 (en) Therapeutic uses of quinazolinedione derivatives
PL2448927T3 (pl) Nowe pochodne (6-okso-1,6-dihydro-pirymidyn-2-ylo)-amidu, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT
IL248077B (en) Formulations, salts and polymers of transnorsertraline and their uses
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
EP2424533A4 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
ZA201300012B (en) Synthesis and use of kinase inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
HU0900647D0 (en) Salts of 7-nitroindoline derivatives and use thereof
PL389364A1 (pl) Nowe zastosowanie pochodnych 2-pirolidonu